Article: Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer.
Research in pharmaceutical sciences
2021 Volume 16, Issue 5, Page(s) 447–454
Abstract: Redirected chimeric antigen receptor (CAR) T-cells can recognize and eradicate cancer cells in a major histocompatibility complex independent manner. Genetic engineering of T cells through CAR expression has yielded great results in the treatment of ... ...
Abstract | Redirected chimeric antigen receptor (CAR) T-cells can recognize and eradicate cancer cells in a major histocompatibility complex independent manner. Genetic engineering of T cells through CAR expression has yielded great results in the treatment of hematological malignancies compared with solid tumors. There has been a constant effort to enhance the effectiveness of these living drugs, due to their limited success in targeting solid tumors. Poor T cell trafficking, tumor-specific antigen selection, and the immunosuppressive tumor microenvironment are considered as the main barriers in targeting solid tumors by CAR T-cells. Here, we reviewed the current state of CAR T-cell therapy in breast cancer, as the second cancer-related death in women worldwide, as well as some strategies adopted to keep the main limitations of CAR T-cells under control. Also, we summarized various approaches that have been developed to enhance the therapeutic outcomes of this treatment in solid tumors targeting. |
---|---|
Language | English |
Publishing date | 2021-08-19 |
Publishing country | Iran |
Document type | Journal Article ; Review |
ZDB-ID | 2400156-9 |
ISSN | 1735-9414 ; 1735-5362 |
ISSN (online) | 1735-9414 |
ISSN | 1735-5362 |
DOI | 10.4103/1735-5362.323911 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.